Nicky Liebermann

Economic Implications of 21-Gene Breast Cancer Risk Assay from the Perspective of an Israeli-Managed Health-Care Organization

Shmuel Klang, Ariel Hammerman, Nicky Liebermann et al. · Value in Health · 2010 · 114 citations · Full text

Economic Implications, Breast Oncology, Preventive Medicine +13

Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry

Salomon M. Stemmer, Mariana Steiner, Shulamith Rizel et al. · npj Breast Cancer · 2017 · 85 citations · Full text

Screening and Diagnosis of Gestational Diabetes Mellitus

Ofra Kalter‐Leibovici, Laurence S. Freedman, Liraz Olmer et al. · Diabetes Care · 2012 · 68 citations · Full text

Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry

Salomon M. Stemmer, Mariana Steiner, Shulamith Rizel et al. · npj Breast Cancer · 2017 · 68 citations · Full text

Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutations

Ron Lewin, Aarón Sulkes, Tzippy Shochat et al. · Breast Cancer Research and Treatment · 2016 · 37 citations

Breast Oncology, Oncology, Tumor Heterogeneity +10